USD 2.28
(2.7%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 | -2.51 Million USD | 55.15% |
2023 | -5.6 Million USD | -8.05% |
2022 | -5.18 Million USD | -136.21% |
2021 | -2.19 Million USD | -151.28% |
2020 | 4.28 Million USD | 142.15% |
2019 | 1.76 Million USD | 8.41% |
2018 | 1.63 Million USD | 1.88% |
2017 | 1.6 Million USD | 666.08% |
2016 | 209.14 Thousand USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q3 | 3.41 Million USD | 136.55% |
2024 Q1 | -4.67 Million USD | -4.88% |
2024 Q4 | 3.41 Million USD | 0.0% |
2024 FY | -2.09 Million USD | 62.69% |
2024 Q2 | -9.34 Million USD | -100.0% |
2023 Q2 | -1.15 Million USD | -100.0% |
2023 Q4 | -4.45 Million USD | -117.01% |
2023 Q3 | -2.05 Million USD | -78.52% |
2023 Q1 | -575.22 Thousand USD | -145.11% |
2023 FY | -5.6 Million USD | -8.05% |
2022 Q1 | -1.44 Million USD | -159.78% |
2022 Q4 | 1.27 Million USD | 210.96% |
2022 Q2 | -2.89 Million USD | -100.0% |
2022 Q3 | -1.14 Million USD | 60.26% |
2022 FY | -5.18 Million USD | -136.21% |
2021 Q3 | -1.68 Million USD | -388.78% |
2021 Q4 | 2.41 Million USD | 243.92% |
2021 FY | -2.19 Million USD | -151.28% |
2021 Q2 | 581.9 Thousand USD | 0.0% |
2021 Q1 | 581.9 Thousand USD | 108.35% |
2020 Q2 | -220.75 Thousand USD | -100.0% |
2020 Q3 | -560.18 Thousand USD | -153.76% |
2020 FY | 4.28 Million USD | 142.15% |
2020 Q1 | -110.37 Thousand USD | -106.24% |
2020 Q4 | -6.96 Million USD | -1143.71% |
2019 Q1 | 663.46 Thousand USD | 121.12% |
2019 FY | 1.76 Million USD | 8.41% |
2019 Q3 | 221.27 Thousand USD | -83.32% |
2019 Q2 | 1.32 Million USD | 100.0% |
2019 Q4 | 1.76 Million USD | 699.67% |
2018 FY | 1.63 Million USD | 1.88% |
2018 Q3 | 1.33 Million USD | 154.57% |
2018 Q4 | 300.05 Thousand USD | -77.48% |
2018 Q1 | 523.32 Thousand USD | 3.09% |
2018 Q2 | 523.32 Thousand USD | -0.0% |
2017 Q4 | 507.65 Thousand USD | 0.0% |
2017 FY | 1.6 Million USD | 666.08% |
2016 FY | 209.14 Thousand USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 46.97 Million USD | 105.355% |
Aquestive Therapeutics, Inc. | -15.1 Million USD | 83.345% |
Collegium Pharmaceutical, Inc. | 166.96 Million USD | 101.506% |
Cosmos Health Inc. | -21.83 Million USD | 88.479% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 87.455% |
Esperion Therapeutics, Inc. | -155.56 Million USD | 98.383% |
Cronos Group Inc. | -81.37 Million USD | 96.909% |
Incannex Healthcare Limited | -30.04 Million USD | 91.627% |
Kala Pharmaceuticals, Inc. | -39.15 Million USD | 93.576% |
Lifecore Biomedical, Inc. | 9.33 Million USD | 126.955% |
Regencell Bioscience Holdings Limited | -4.73 Million USD | 46.9% |
Sunshine Biopharma, Inc. | -4.78 Million USD | 47.439% |
Sunshine Biopharma, Inc. | -4.78 Million USD | 47.439% |
SCYNEXIS, Inc. | 72.66 Million USD | 103.461% |
Safety Shot Inc | -12.18 Million USD | 79.357% |
Theratechnologies Inc. | -10.62 Million USD | 76.332% |
Alpha Teknova, Inc. | -35.56 Million USD | 92.927% |
Universe Pharmaceuticals INC | -3.52 Million USD | 28.682% |
Pacira BioSciences, Inc. | 87.67 Million USD | 102.869% |
Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 46.496% |
Dynavax Technologies Corporation | -37.02 Million USD | 93.207% |
Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 101.203% |
Radius Health, Inc. | -3.92 Million USD | 35.918% |
Alvotech | -354.86 Million USD | 99.291% |
Intra-Cellular Therapies, Inc. | -159.38 Million USD | 98.422% |
SIGA Technologies, Inc. | 83.62 Million USD | 103.008% |
Shineco, Inc. | -17.06 Million USD | 85.262% |
Silver Spike Investment Corp. | 7.34 Million USD | 134.267% |
Journey Medical Corporation | -2.07 Million USD | -21.332% |
Petros Pharmaceuticals, Inc. | -13.61 Million USD | 81.529% |
Embecta Corp. | 221.5 Million USD | 101.136% |
Harrow Health, Inc. | 580 Thousand USD | 533.658% |
Procaps Group, S.A. | 38.97 Million USD | 106.454% |
Biofrontera Inc. | -22.67 Million USD | 88.909% |
DURECT Corporation | -36.88 Million USD | 93.181% |
PainReform Ltd. | -9.58 Million USD | 73.756% |
Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 52.264% |
OptiNose, Inc. | -22.74 Million USD | 88.943% |
RedHill Biopharma Ltd. | 12.63 Million USD | 119.911% |
Organogenesis Holdings Inc. | 12.52 Million USD | 120.082% |
Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 59.503% |
ProPhase Labs, Inc. | -21.61 Million USD | 88.362% |
Phibro Animal Health Corporation | 53.31 Million USD | 104.718% |
Procaps Group S.A. | 52.32 Million USD | 104.807% |
TherapeuticsMD, Inc. | -8.52 Million USD | 70.489% |
Viatris Inc. | 766.2 Million USD | 100.328% |
Rockwell Medical, Inc. | -6.67 Million USD | 62.291% |
Aytu BioPharma, Inc. | -5.25 Million USD | 52.128% |
Tilray Brands, Inc. | -174.74 Million USD | 98.561% |
PetIQ, Inc. | 60.01 Million USD | 104.191% |
Talphera, Inc. | -16.88 Million USD | 85.107% |
Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.002% |
Alimera Sciences, Inc. | -1.47 Million USD | -70.987% |
Assertio Holdings, Inc. | -243.53 Million USD | 98.967% |
Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 57.314% |
Avadel Pharmaceuticals plc | -137.84 Million USD | 98.175% |
Hempacco Co., Inc. | -8.81 Million USD | 71.458% |
Alvotech | -354.86 Million USD | 99.291% |
Lantheus Holdings, Inc. | 364.64 Million USD | 100.69% |
Kamada Ltd. | 10.06 Million USD | 124.992% |
Currenc Group, Inc. | -6.64 Million USD | 62.153% |
Indivior PLC | -4 Million USD | 37.12% |
Evoke Pharma, Inc. | -7.43 Million USD | 66.152% |
Flora Growth Corp. | -50.35 Million USD | 95.005% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 87.455% |
Evolus, Inc. | -49.23 Million USD | 94.891% |
HUTCHMED (China) Limited | 18.37 Million USD | 113.688% |
Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 101.277% |
Akanda Corp. | -10.05 Million USD | 74.976% |